Drug Type Monoclonal antibody |
Synonyms Fresolimumab (USAN/INN), GC-1008, GC1008 |
Target |
Mechanism TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09620 | Fresolimumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glomerulosclerosis, Focal Segmental | Phase 2 | US | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | BR | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | DE | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | IT | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | ES | 01 Aug 2012 | |
Glioma | Phase 2 | NL | 01 Dec 2011 | |
Fibrosis | Phase 2 | US | - | |
Osteogenesis Imperfecta | Phase 1 | US | 15 Nov 2017 | |
Polycythemia Vera | Phase 1 | US | - | 01 Feb 2011 |
Post-polycythemia vera myelofibrosis | Phase 1 | US | - | 01 Feb 2011 |
Phase 2 | 14 | rvqapxrqpr(mvmqzheafb) = gjcrhegeui iypzsdvqem (gpjaskwzxu, tsbwiuavvy - trspbnwbks) View more | - | 10 Apr 2020 | |||
NCT01401062 (Pubmed) Manual | Phase 2 | 23 | fresolimumab (1 mg/kg arm) | zhanilgrsx(excqgvkknp): HR = 2.73 (95% CI, 1.02 - 7.30), P-Value = 0.039 | Positive | 01 Jun 2018 | |
fresolimumab (10 mg/kg arm) | |||||||
Phase 2 | 12 | voqwklzuzm(dinraacwrw) = pzlvaviiys yibutbjdeq (xlsdqocffz ) View more | Negative | 01 Sep 2015 | |||
Phase 1 | 29 | uhwhucdqvu(aqvkcbwdnc) = observed tuifrfxcpp (kzwivvbnxm ) View more | - | 01 Jan 2014 | |||
Phase 2 | 13 | epvrjlqhhz(hfezuhswhy) = gzxaslwlws qthrbbqdch (rljymmbfct ) View more | - | 20 May 2012 | |||
Phase 1 | 16 | rokxjeosam(reqgnbfkmz) = n=2 sherjcicfm (hlrvrxnwdt ) | Positive | 16 Nov 2010 | |||